leqembi news - Search News

Seeking Alpha on MSN · 1d

Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s Alzheimer’s drug Leqembi. The investment bank said it doesn’t expect Biogen (BIIB) to return to growth until 2026,

Business Insider · 1d

Needham downgrades Biogen to Hold on lack of share catalysts

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares

ca.investing.com on MSN · 1d

Needham downgrades Biogen on slow growth of Alzheimer's drug

Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months. The brokerage stated that Leqembi’s sales

Worldcrunch on MSN1d

Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Leqembi Okayed for Subset of Early Alzheimer’s Patients

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved

Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

1d

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...

4don MSN

European committee takes a second look at Alzheimer’s drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

4d

Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe

The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...

EU Backs Leqembi: A Breakthrough in Alzheimer's Treatment

The European Union's drugs regulator has recommended approval for Eisai and Biogen's Alzheimer's drug Leqembi. This marks a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results